Nanoplatforms for targeted molecular imaging in living subjects

被引:448
作者
Cai, Weibo [1 ]
Chen, Xiaoyuan [1 ]
机构
[1] Stanford Univ, Dept Radiol & Bio X Program, MIPS, Stanford, CA 94305 USA
关键词
cancer; molecular imaging; nanomedicine; nanoplatforms; nanotechnology;
D O I
10.1002/smll.200700351
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Molecular or personalized medicine is the future of patient management and molecular imaging plays a key role towards this goal. Recently, nanoplatform-based molecular imaging has emerged as an interdisciplinary field, which involves chemistry, engineering, biology, and medicine. Possessing unprecedented potential for early detection, accurate diagnosis, and personalized treatment of diseases, nanoplatforms have been employed in every single biomedical imaging modality, namely, optical imaging, computed tomography, ultrasound, magnetic resonance imaging, singlephoton-emission computed tomography, and positron emission tomography. Multifunctionality is the key advantage of nanoplatforms over traditional approaches. Targeting ligands, imaging labels, therapeutic drugs, and many other agents can all be integrated into the nanoplatform to allow for targeted molecular imaging and molecular therapy by encompassing many biological and biophysical barriers. In this Review, we will summarize the current stateof-the-art of nanoplatforms for targeted molecular imaging in living subjects.
引用
收藏
页码:1840 / 1854
页数:15
相关论文
共 168 条
[41]   In vivo imaging of quantum dots encapsulated in phospholipid micelles [J].
Dubertret, B ;
Skourides, P ;
Norris, DJ ;
Noireaux, V ;
Brivanlou, AH ;
Libchaber, A .
SCIENCE, 2002, 298 (5599) :1759-1762
[42]   Cell-penetrating peptides:: Mechanisms and applications [J].
El-Andaloussi, S ;
Holm, T ;
Langel, Ü .
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (28) :3597-3611
[43]   Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to αvβ3 [J].
Ellegala, DB ;
Poi, HL ;
Carpenter, JE ;
Klibanov, AL ;
Kaul, S ;
Shaffrey, ME ;
Sklenar, J ;
Lindner, JR .
CIRCULATION, 2003, 108 (03) :336-341
[44]  
Enochs WS, 1999, JMRI-J MAGN RESON IM, V9, P228, DOI 10.1002/(SICI)1522-2586(199902)9:2<228::AID-JMRI12>3.3.CO
[45]  
2-B
[46]  
Even-Sapir E, 2003, J NUCL MED, V44, P1413
[47]   Cancer nanotechnology: Opportunities and challenges [J].
Ferrari, M .
NATURE REVIEWS CANCER, 2005, 5 (03) :161-171
[48]   Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans [J].
Fire, A ;
Xu, SQ ;
Montgomery, MK ;
Kostas, SA ;
Driver, SE ;
Mello, CC .
NATURE, 1998, 391 (6669) :806-811
[49]   Novel MRI contrast agent for molecular imaging of fibrin implications for detecting vulnerable plaques [J].
Flacke, S ;
Fischer, S ;
Scott, MJ ;
Fuhrhop, RJ ;
Allen, JS ;
McLean, M ;
Winter, P ;
Sicard, GA ;
Gaffney, PJ ;
Wickline, SA ;
Lanza, GM .
CIRCULATION, 2001, 104 (11) :1280-1285
[50]   Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging [J].
Frias, Juan C. ;
Ma, Yanqing ;
Williams, Kevin Jon ;
Fayad, Zahi A. ;
Fisher, Edward A. .
NANO LETTERS, 2006, 6 (10) :2220-2224